Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-cash Items: 2017-2024

Historic Non-cash Items for Protagonist Therapeutics (PTGX) over the last 6 years, with Dec 2024 value amounting to $152.9 million.

  • Protagonist Therapeutics' Non-cash Items rose 154.83% to $152.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $152.9 million, marking a year-over-year increase of 154.83%. This contributed to the annual value of $4.9 million for FY2024, which is 4.04% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Non-cash Items stood at $152.9 million for Q4 2024, which was up 154.83% from $60.0 million recorded in Q4 2023.
  • In the past 5 years, Protagonist Therapeutics' Non-cash Items registered a high of $152.9 million during Q4 2024, and its lowest value of $1.7 million during Q2 2022.
  • Over the past 3 years, Protagonist Therapeutics' median Non-cash Items value was $5.7 million (recorded in 2022), while the average stood at $35.0 million.
  • The largest annual percentage gain for Protagonist Therapeutics' Non-cash Items in the last 5 years was 1,584.97% (2022), contrasted with its biggest fall of 93.28% (2022).
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Non-cash Items stood at $40.0 million in 2020, then spiked by 156.75% to $102.7 million in 2021, then tumbled by 93.28% to $6.9 million in 2022, then spiked by 769.57% to $60.0 million in 2023, then skyrocketed by 154.83% to $152.9 million in 2024.
  • Its last three reported values are $152.9 million in Q4 2024, $60.0 million for Q4 2023, and $4.4 million during Q2 2023.